The research is preclinical and ongoing, which is why BPC-157 is prescribed off-label
M.tb infection downregulates Sirt1 expression, which is crucial for negatively modulating inflammatory responses by inhibiting the activation of TAK1, MAPK and NF-B pathways and reducing IL-6 and TNF- levels
However, in the LEADER trial, a non-significant trend towards DRP was observed for liraglutide (121)
The DURATION-1 trial reported a 4.7 mmHg reduction with weekly 2 mg exenatide [35], while more modest decreases (0.652.6 mmHg) were observed in other trials [14, 16, 19, 20, 23]
The mechanisms of TB-500 are still being investigated, but known actions of TB4 include: Binding as an actin-binding protein to inhibit the polymerization of globular actin (G-actin) into filamentous actin (F-actin), known as actin sequestration, which results in higher G-actin levels and increased cellular motility [23, 24] TB4s ability to increase cellular motility may help progenitor cells to reach sites of injury and initiate tissue recovery [25]